ala

(redirected from Aminolevulinic acid)
Also found in: Dictionary, Thesaurus, Medical, Acronyms, Wikipedia.
Related to Aminolevulinic acid: porphyria

ala

[′ā·lə]
(biology)
A wing or winglike structure.

ala

1. An alcove or small room opening off the atrium of an ancient Roman house.
2. A small room on each side of a cella.
References in periodicals archive ?
This approach reduced the incubation time of aminolevulinic acid (ALA) to 20 minutes, with comparable results to 1-hour ALA incubation times.
biloba (Xu et al., 2008) and 5- aminolevulinic acid induced the transcription of a CHI gene that regulates total flavonoid accumulation in the leaves of G.
These tests revealed increased levels of coproporhyrin and porphyrin precursors such as porphobilinogen (PBG) and aminolevulinic acid. A diagnosis of acute porphyria was thereby confirmed.
Optical treatments possess the potential to improve inflammatory acne on a short-term basis with the most consistent outcomes for photodynamic therapy [up to 68% improvement with aminolevulinic acid (ALA), methyl- aminolevulinic acid (MAL) and red light].
Fenske said he often uses Levulan (aminolevulinic acid) plus blue light, but to treat and kill bacteria deep in the sebaceous glands, "I would use red light and Metwixia [MAL]," he said.
259) hypothesized that associations might be modified by a common variant allele of the aminolevulinic acid dehydratase (ALAD) gene, which encodes the primary carrier protein for lead in blood.
Another topical agent available in Europe and Australia but not yet in the United States, methyl aminolevulinic acid cream (Metvix), is applied and left on the skin for 3 hours, followed by 10 minutes of exposure to red light.
In fact, the accumulation of aminolevulinic acid (ALA) due to the inhibition of ALAD activity by Pb is responsible for the adverse neurological effects of lead poisoning.
Alnylam Pharmaceuticals announced that the ENVISION Phase 3 study of givosiran, an investigational RNAi therapeutic targeting aminolevulinic acid synthase 1 in development for the treatment of acute hepatic porphyria, met its primary efficacy endpoint and the majority of secondary endpoints.
It's not unusual for a new dermatology procedure or agent to debut in Europe and later come to the United States, but, in the case of daylight PDT, several factors make a direct comparison difficult, including disparate formulations of aminolevulinic acid (ALA) approved on either side of the Atlantic.